Clinical Trial Update: A Phase I/II Dose Escalation Study of the Tumor-targeting Human L19-IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Dacarbazine for Patients With Metastatic Melanoma [Phase 1, Phase 2]

View source ↗

Summary

Phase I/II dose-escalation study of L19-IL2 antibody-cytokine fusion protein with dacarbazine for metastatic melanoma (Phase 1/Phase 2).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Dacarbazine (dacarbazine)
• L19-IL2 (Interleukin-2 fused to the L19 antibody (L19-IL2))

Snippet

Sponsor: Philogen S.p.A. | Conditions: Metastatic Melanoma Stage IV | Phase 1, Phase 2 | Status: UNKNOWN